BackCastle Biosciences Overview
Castle Biosciences Inc

Castle Biosciences Target Price

See Castle Biosciences's analyst price targets ($39) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$32.32

Average Target Price

$38.7519.9% upside

4 analysts in the last 4 months

High: $44 | Low: $35

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-03BTIGSung Ji Nam$4436.1% upsideOpen
2026-07-31Robert W. Baird$3611.4% upsideOpen
2026-06-24Roth Capital$4023.8% upsideOpen
2026-05-29KeyBanc$358.3% upsideOpen
2026-04-20Canaccord GenuityKyle Mikson$4023.8% upsideOpen
2026-01-29KeyBancPaul Knight$5054.7% upsideOpen
2026-01-26GuggenheimSubbu Nambi$4745.4% upsideOpen
2026-01-12Lake Street$5260.9% upsideOpen
2026-01-05Guggenheim$4333% upsideOpen
2025-12-22Canaccord Genuity$5054.7% upsideOpen
2025-12-12BTIGMark Massaro$5054.7% upsideOpen
2025-03-28GuggenheimSubbu Nambi$307.2% downsideOpen
2025-02-28Robert W. Baird$3714.5% upsideOpen
2024-11-05BTIGSung Ji Nam$4539.2% upsideOpen
2024-11-05Robert W. BairdCatherine Schulte$3920.7% upsideOpen
2024-11-05KeyBancPaul Knight$3611.4% upsideOpen
2024-10-29Canaccord GenuityKyle Mikson$4230% upsideOpen
2024-10-14BTIGSung Ji Nam$4023.8% upsideOpen
2024-08-06BTIGSung Ji Nam$358.3% upsideOpen
2022-11-04Robert W. BairdCatherine Schulte Analyst$4126.9% upsideOpen

Castle Biosciences (CSTL) FAQ

Castle Biosciences's target price stands at $39. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $39 for CSTL implies 19.9% upside versus today's price ($32.32). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Castle Biosciences's target price evolved across reporting periods, while the comparison chart places CSTL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Castle Biosciences's reading of $39 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.